BCBSTX Spravato Reimbursement Rates in Texas (2026)

For a Texas practice weighing a Spravato program, the first decision is whether or not to buy and bill. Blue Cross and Blue Shield of Texas publishes the rates behind that decision in its machine readable files. In Texas they say let a specialty pharmacy supply the drug.

The figures come from BCBSTX’s August 2026 machine readable files, 38 gigabytes of pricing data unpacked, pooled across its Texas commercial network files. We kept dollar rates billed as professional claims in the office setting. The files also carry percent-of-charge rows and thousands of placeholder rows priced at exactly zero, and we excluded them all. The office filter matters because the bundled codes pay differently when the drug is billed on a facility claim. We matched each NPI against the federal NPPES registry, kept individual psychiatric prescribers practicing in Texas, and computed statistics over distinct provider-rate pairs. If TMS is also something you offer, the companion analysis of BCBSTX’s TMS rates in Texas uses the same method and the same data.

BCBSTX Negotiated Spravato Rates in Texas

J0013 pays for the drug alone, per milligram. G2082 and G2083 are bundles that pay for the visit, the drug and the required two-hour observation in one amount. G2082 covers doses up to 56 mg and G2083 covers doses above 56 mg.

Rates extracted from BCBSTX’s August 2026 Texas machine readable files.

J0013 replaced the retired esketamine code S0013 on January 1, 2026. Our full scan of BCBSTX’s files found J0013 priced throughout and no S0013 rows at all. Texas Medicaid made the same switch on the same date and converted existing authorizations automatically.

Should Texas Practices Buy and Bill Spravato?

Not at BCBSTX’s median rates. Every buy-and-bill route pays less than the drug costs. Start with the drug. Spravato comes in 28 mg devices that cost about $426 to $431 each at the August 2026 national average acquisition cost. The drug for a 56 mg dose costs roughly $853, and for an 84 mg dose roughly $1,294.

Now compare the two ways to bill it:

• Bundled codes. An 84 mg session billed as one G2083 pays $866.11 at the median, about $430 less than the drug alone. A 56 mg session billed as G2082 pays $610.65 against roughly $853 of drug, about $240 short.
• Per-milligram code. BCBSTX pays a flat $15.02 per mg for J0013 statewide. An 84 mg claim bills $1,261.68 against roughly $1,294 of drug, about $30 short. A 56 mg claim bills $841.12 against roughly $853, about $10 short.

Those losses come before any staff time. In New York we found a thin positive margin on the per-milligram code, but in Texas even that is gone. An induction month is one 56 mg session and seven at 84 mg. You would pay about $9,920 for one patient’s drug before the first claim pays, then bill $9,672.88 back. Each new patient loses roughly $245 on the drug alone.

So let a REMS-certified specialty pharmacy supply the drug, and build the program’s revenue on the visit, the observation time and the psychotherapy around it, unless you have contracted rates well above the median. BCBSTX’s rates for therapy codes are on our Texas behavioral health rates page.

Our extraction also shows BCBSTX has negotiated rates for both prolonged clinical staff codes, 99415 and 99416. Some payers price only one. BCBSTX publishes no bulletin on how it wants observation time billed, so confirm the coding with the plan before counting on that revenue.

Check your own contract’s numbers:

What Does BCBSTX Require to Approve Spravato in Texas?

One failed antidepressant, a confirmed diagnosis with a qualifying severity score, and no active substance use disorder. BCBSTX reviews esketamine under HCSC medical policy RX501.105, effective January 1, 2026.

The policy’s main requirements are:

• An inadequate response to one antidepressant after an adequate trial. Most payers require two drugs from two classes.
• A diagnosis confirmed by structured clinical interview, with a qualifying severity score such as MADRS 28 or higher or PHQ-9 10 or higher.
• No active substance use disorder. Patients qualify after at least a month of abstinence.
• Esketamine alone or with an oral antidepressant, in line with the FDA’s 2025 approval of monotherapy.

Initial approvals run three months. Renewals require documented improvement on a rating scale. A separate pathway for depression with acute suicidal ideation or behavior approves 28 days at a time and still requires an oral antidepressant alongside.

Under the same HCSC manual, Spravato is now easier to get approved than TMS. The TMS policy requires two failed antidepressants from two classes plus a failed psychotherapy trial. The esketamine policy requires one failed antidepressant. A patient who does not yet qualify for TMS may already qualify for Spravato, which is worth raising with referring clinicians.

Prior authorization for the drug codes starts October 1, 2026. BCBSTX’s commercial authorization list adds J0013 and G2083 from that date, and BCBSTX reviews them itself. G2082, the up-to-56 mg bundle, is not on the list.

Two Texas laws limit how many drugs a plan can make a patient try first. They cover state-regulated plans, which BCBSTX marks with “TDI” on the member ID card. Self-funded employer plans generally follow federal rules instead.

• The one-drug limit. Insurance Code section 1369.0547 applies to plans issued or renewed on or after January 1, 2024. For adults with a serious mental illness, including major depressive disorder, a plan cannot require more than one failed drug before it covers the prescribed one. On TDI plans, BCBSTX’s one-antidepressant rule is the most Texas law allows.
• The override. Section 1369.0546 lets you request an exception. The plan must grant it if the chart shows the patient stopped the required drug, or one in its class, because it failed or caused an adverse event. Send the request on the Texas Department of Insurance’s standard form. If the plan does not deny it within 72 hours, it is granted. The limit is 24 hours if you state that a denial would likely cause the patient’s death or serious harm.

Both laws are written for prescription drugs, and esketamine is one. BCBSTX may still treat its antidepressant rule as a medical necessity criterion rather than a step-therapy rule. Cite the sections in the request, and appeal a denial like any other adverse determination.

How Does Texas Medicaid Handle Spravato?

Texas Medicaid covers esketamine for adults 18 and older with prior authorization, in approvals of up to six months. TMS, by contrast, does not appear to be a Texas Medicaid benefit.

The state’s criteria follow the commercial pattern. Patients need treatment-resistant depression with a documented antidepressant failure (esketamine alone or with an oral antidepressant), or major depression with acute suicidal ideation (with an oral antidepressant). Treatment must happen in a REMS-certified setting with two hours of monitoring.

Billing moved to J0013 on January 1, 2026. The state’s fee for the new code was still pending a rate hearing when we checked in September 2026, so this page quotes no Medicaid dollar figure. Check the TMHP fee schedule for the adopted rate.

For a commercial program, Medicaid coverage matters mostly because a REMS-certified site can serve both groups of patients. Most Texas counties have no practicing psychiatrist, so certified sites are hard to find.

What Do Texas Practices Charge Self-Pay Patients for Spravato?

Published self-pay prices run from $179 to about $1,200 per session. An Austin clinic lists $179 per dose, including coordination with the pharmacy that supplies the drug. Another Austin practice lists a $325 initial consultation and $450 per treatment session. A Bellaire clinic says sessions without insurance typically run about $600 to $1,200.

Prices vary widely, and practices do not all say whether the drug is included. Compare them to your contract with care.

What This Means for Your Program

At BCBSTX’s median rates, buying Spravato loses money in Texas. Let a certified specialty pharmacy supply the drug, and bill the clinical work. Every figure above comes from BCBSTX’s own federal disclosure, filtered to dollar rates on professional office claims for Texas psychiatric prescribers. The medians are market references, not anyone’s contract.

Verify each patient’s plan type and authorization status before the first dose. If you are offered a bundled-code contract, compare it to the drug cost before signing. At the median it does not cover the drug.

Fuse helps practices with this work. We offer CPT-level verification of benefits before treatment starts, reimbursement checks against past claims, and analytics that flag the gap between contracted and paid before it compounds. Reach out if you think we could help.

Disclaimer: This article uses rate information from the Machine Readable Files that Blue Cross and Blue Shield of Texas publishes under the federal Transparency in Coverage rule. These files are posted to satisfy the regulation, not to be read. The files behind this analysis unpack to 38 gigabytes of raw pricing data that no spreadsheet can open. Fuse built its own software to extract and verify the figures above. This analysis focuses on a single payer and will not reflect rates from all available insurance options in Texas. Fuse makes every effort to provide accurate and current information, but healthcare pricing and coverage policy change frequently, and individual circumstances affect actual payment. This information does not guarantee specific pricing. Practices should verify current rates and criteria directly with BCBSTX before relying on them for billing or negotiation decisions.